Drug Trial Radar · NCT07172516
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Aug 8, 2025
Primary completion
Jun 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Xenon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants diagnosed with bipolar I or II disorder who are currently in a depressive episode (bipolar depression).
Conditions
- Bipolar Disorder
- Bipolar Depression
- Bipolar I Disorder
- Bipolar II Disorder
Interventions
AzetukalnerDrug
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
PlaceboDrug
Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6.Time frame: Baseline to Week 6
Locations
44 sites in 4 countries. Site status is shown where the registry gives one.
Noble Clinical Research
Tucson, Arizona
Woodland International Research Group
Little Rock, Arkansas
Woodland Research Northwest
Rogers, Arkansas
Clinical Innovations Inc
Bellflower, California
ProScience Research Group
Culver City, California
ATP Clinical Research
Orange, California
NRC Research Institute
Orange, California
Clinical Innovations Inc
Riverside, California
Sunwise Clinical Research
Walnut Creek, California
PharmaSouth Research, LLC
Coral Gables, Florida
Sarkis Clinical Research
Gainesville, Florida
Clinical Neuroscience Solutions, LLC
Jacksonville, Florida
Central Miami Medical Institute
Miami, Florida
Clinical Neuroscience Solutions, LLC
Orlando, Florida
Synexus Clinical Research, Inc.
Atlanta, Georgia
Atlanta Center for Medical Research
Atlanta, Georgia
CenExel iResearch
Decatur, Georgia
Denali Health Atlanta, LLC
Stone Mountain, Georgia
Revival Research Institute
Elgin, Illinois
Advanced Quality Medical Research
Orland Park, Illinois
Psychiatric Care and Research Center
O'Fallon, Missouri
Redbird Clinical Research, LLC
Las Vegas, Nevada
Lumina Clinical Research Center
Cherry Hill, New Jersey
Bio Behavioral Health
Toms River, New Jersey
Integrative Clinical Trials LLC
Brooklyn, New York
Neurobehavioral Research Inc
Cedarhurst, New York
Richmond Behavioral Associates
Staten Island, New York
DelRicht Research
Charlotte, North Carolina
Lehigh Center for Clinical Research
Allentown, Pennsylvania
Clinical Neuroscience Solutions, LLC
Memphis, Tennessee
Elevate Synapsis, LLC
Atascocita, Texas
Memorial Hermann Village
Houston, Texas
Grayline Research Center
Wichita Falls, Texas
Core Clinical Research
Everett, Washington
Multiprofile Hospital for Active Treatment "Dr. Hristo Stambolski"
Kazanlak, Bulgaria
State Psychiatric Hospital Lovech
Lovech, Bulgaria
Saint Naum Medical Center
Sofia, Bulgaria
Diagnostic and Consulting Center XI Sofia
Sofia, Bulgaria
Diagnostics-Consultative Center Mladost M Varna OOD
Varna, Bulgaria
Universitätsklinikum Carl Gustav Carus, TU Dresden - Klinik und Poliklinik für Psychiatrie
Dresden, Germany
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.